Efficacy and safety of treatment of patients suffering from severe forms of psoriasis

Cite item


A comparative clinical, laboratory and ultrasonic assessment of the efficacy and safety of Infliximab (Remicade®) and cyclosporine A as well as photochemotherapy on the basis of Oxsoralen in 90 patients suffering from severe plaque psoriasis and psoriatic erythroderma at the progression stage. Clinical and ultrasonic assessment demonstrated that Infliximab (Remicade®) is a highly efficient drug for treatment of severe plaque psoriasis and psoriatic erythroderma providing an evident reduction in inflammatory changes both in the epidermis and dermis as well as normalizing epidermal keratinization processes. A long-term maintenance treatment with Infliximab positively modifies the course of severe psoriasis in patients and is quite safe. A course of treatment with cyclosporine A and general photochemotherapy is quite efficient under similar conditions but its action is short-term. After the completion of the above-mentioned therapy, patients develop dermatosis relapses of the same severity and extent during a year of follow-up. According to the ultrasonic examination results, a course of treatment with cyclosporine A and photochemotherapy has a partial effect on pathohistology processes in psoriatic patients as well as entails a number of adverse effects.


  1. Псориаз. Клинические рекомендации РОДВ. М.: ДЭКС- Пресс, 2008. 56 с.
  2. Feldman S.R., Koo J.Y., Menter A., Bagel J. Decision points for the initiation of systemic treatment for psoriasis // J. Am. Acad. Dermatol. 2005. № 53. P. 101 - 107.
  3. Winterfield L.S., Menter A., Gordon K. et al. Psoriasis treatment current and emerging directed therapies // Ann. Rheum. Dis. 2005. № 64. P. 1187-1190.
  4. Рациональная фармакотерапия заболеваний кожи и инфекций, передаваемых половым путем. Рук. для практикующих врачей / А.А. Кубанова, В.И. Кисина, Л.А. Блатун и др. под общ. Ред. А.А. Кубановой, В.И. Кисиной. М.: Литтерра, 2005. 882 с.
  5. European S-3-Guidelines on the systemic treatment of psoriasis vulgaris // JEADV. 2009. Vol. 23. supp. 2. P. 5-70.
  6. Моисеев С.В. Индукционная и поддерживающая терапия инфликсимабом при псориазе // Клин. фармакол. и тер. 2006. № 4. С. 15-19.
  7. Barry J., Kirby B. Novel biologic therapies for psoriasis // Expert. Opin. Biol. Ther. 2004. № 4. P. 975-987.
  8. Van Vollenhoven R.F. Switching between biological agents // Clin. Exp. Rheumatol. 2004. № 22. S. 115-121.
  9. Reich K., Nestle F., Papp K. et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial // Lancet. 2006. № 366. P. 1367-1374.
  10. Gottilieb A., Evans R., Li S. et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a randomised, double-blind, placebocontrolled trial // J. Am. Acad. Dermatol. 2004. № 51. P. 534-542.


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 60448 от 30.12.2014.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies